ライフサイエンスコーパス: DALY

1 DALY risk factors varied by age, with child and maternal

2 DALYs differed by age groups and regions, but not by gen

3 DALYs due to oral conditions increased 20.8% between 199

4 DALYs for the various device/voltage combinations were l

5 DALYs from non-communicable diseases--especially ischaem

6 DALYs were calculated for 291 causes, 20 age groups, bot

7 additional 67.2 million illnesses or 492,000 DALYs.

8 ution (1,448,612 DALYs) and malaria (725,000 DALYs) in these countries.

9 on) and foodborne toxoplasmosis with 825,000 DALYs (95% UI 561,000-1.26 million) resulted in the high

10 han the HTI of coal electricity (0.016-0.024 DALY/GWh versus 0.69-1.7 DALY/GWh).

11 ost [51 d (-0.14 DALYs; 95% CI: -0.21, -0.08 DALYs) and 58 d (-0.16 DALYs; 95% CI: -0.23, -0.09 DALYs

12 and 58 d (-0.16 DALYs; 95% CI: -0.23, -0.09 DALYs), respectively].

13 722 DALYs, with a range of 814,934-1,557,121 DALYs, depending on the weighting factor used.

14 er healthy life years were lost [51 d (-0.14 DALYs; 95% CI: -0.21, -0.08 DALYs) and 58 d (-0.16 DALYs

15 95% CI: -0.21, -0.08 DALYs) and 58 d (-0.16 DALYs; 95% CI: -0.23, -0.09 DALYs), respectively].

16 /=500 cells/microL ranged from $237 to $1691/DALY compared to 2010 guidelines; in Zambia, expanded el

17 .46 million in health-care costs and 806,170 DALYs.

18 tes for ischaemic stroke fell by 14% (9-19), DALYs lost by 17% (-11 to 21%), and mortality-to-inciden

19 s) with percentage of total 2010 DALYs, 2010 DALY rank, and DALY percentage change from 1990 to 2010

20 and protocols) with percentage of total 2010 DALYs, 2010 DALY rank, and DALY percentage change from 1

21 representation and percentage of total 2010 DALYs.

22 IV-positive persons ranged from $131 to $241/DALY and in Vietnam eligibility for CD4 </=500 cells/mic

23 mortality rates reduced by 23% (-18 to 25%), DALYs lost by 25% (-21 to 28), and mortality-to-incidenc

24 billion in health-care costs and 29,385,250 DALYs.

25 bility for CD4 </=500 cells/microL cost $290/DALY.

26 d congenital heart anomaly burden (1629/3049 DALYs per 100 000) was attributed to behavioral or metab

27 13% (95% CI 6-18), mortality by 37% (19-39), DALYs lost by 34% (16-36), and mortality-to-incidence ra

28 Tp-SP3+ to 1000 pregnant women averted 113.4 DALYs at an incremental cost of $825.67 producing an inc

29 de, from 1.3 x 10(-8) and up to 3.4 x 10(-4) DALY per blue-collar worker labor hour.

30 burden of disease might be reduced by 56,400 DALYs, and life expectancy might increase by 0.15 y for

31 al [UI], 43-419) and 1976 (95% UI, 757-4067) DALYs, respectively.

32 edestrians (health loss of between 34 and 41 DALYs per 100 000 population).

33 tly by 19% (1-15), mortality by 38% (32-43), DALYs lost by 39% (32-44), and mortality-to-incidence ra

34 incurs US$474 in health-care costs and 0.51 DALYs annually.

35 d congenital heart anomaly burden (4439/5199 DALYs) in high-income countries.

36 average net present value of $3456 and 3.57 DALYs.

37 5964 DALYs (27 per 1000 individuals) were lost due to hip fra

38 4150 (69.6%) DALYs were attributed to disability.

39 ative guideline for drinking water of 10(-6) DALYs per person per year.

40 burdens for outdoor air pollution (1,448,612 DALYs) and malaria (725,000 DALYs) in these countries.

41 ricity (0.016-0.024 DALY/GWh versus 0.69-1.7 DALY/GWh).

42 and that these exposures resulted in 828,722 DALYs, with a range of 814,934-1,557,121 DALYs, dependin

43 (i.e. dominating current guidelines) to $749/DALY.

44 247), 5463 deaths (1401-21,497), and 172,823 DALYs (44,079-676,465).

45 ALYs globally (1.9% of all YLDs; 0.6% of all DALYs), implying an average health loss of 224 years per

46 t associated with age-standardised death and DALY rates in 2015.

47 age of total 2010 DALYs, 2010 DALY rank, and DALY percentage change from 1990 to 2010 for 15 skin con

48 pidly climbed, with age-standardised YLL and DALY rates increasing more than 130% by 2013.

49 (0.45-0.89) to 0.87 million (0.61-1.18); and DALYs from 31.7 million (30.2-33.3) to 42.5 million (39.

50 discount rate of 3% to adjust all costs and DALYs to present-day values.

51 Direct health-care costs and DALYs were estimated for coronary heart disease, stroke,

52 inued to rank highly as a cause of death and DALYs, especially in HICs.

53 with estimates of cause-specific deaths and DALYs from the Global Burden of Disease Study 2010, to c

54 ally, and the number with related deaths and DALYs lost, is increasing, with most of the burden in lo

55 Deaths and DALYs related to risk factors were based on systematic r

56 number of deaths (21% and 20% increase), and DALYs lost (18% and 14% increase).

57 The pace of reduction in mortality and DALYs in many leading causes has largely levelled off si

58 ietary patterns (per SD change in score) and DALYs were estimated by using a 2-part model and adjuste

59 the UK's rank for age-standardised YLLs and DALYs for their leading causes compared with EU15+ in 19

60 We evaluated attributable DALYs for 17 risk factors (air pollution and environment

61 ted the incremental cost per DALY averted ($/DALY) to compare competing strategies.

62 We compared funding with disease burden (DALYs and mortality) to show low levels of investment re

63 d with a lower disease burden as assessed by DALYs.

64 0 years or older at recruitment to calculate DALYs.

65 We calculated DALYs as the sum of years of life lost (YLLs) and years

66 We compared DALYs due to cutaneous leishmaniasis for 152 countries u

67 presentation when matched with corresponding DALYs.

68 nted in CDSR when matched with corresponding DALYs.

69 highly cost-effective, with an average cost/DALY averted of US$11 (range: US$2-US$48).

70 Crude DALYs per 1000 decreased by 23% (472 per 1000 to 361 per

71 ath, disability-adjusted life years (DALYs), DALY-attributable risk factors, years of life lived with

72 million cases of diarrhea, 109000 diarrheal DALYs, and 1560 deaths each year.

73 d of US$500 per DALY averted, and discounted DALYs and costs at 3% per year.

74 ively compared with the potential downstream DALY benefits, as lives saved, during the use phase.

75 We estimated DALYs for 195 countries divided into 21 world regions, i

76 an increase of 2.7% for deaths and 1.1% for DALYs.

77 cohol misuse was the highest risk factor for DALYs (7.0% overall, 10.5% for males, and 2.7% for femal

78 ood pressure was the leading risk factor for DALYs in 2013, with an increase of 83.3% since 1990.

79 Unsafe sex as a risk factor for DALYs increased from the 13th rank to the second for bot

80 Risk factors for DALYs varied by country.

81 es, and a Monte Carlo simulation to generate DALYs by WHO subregion.

82 FINDINGS: Global DALYs remained stable from 1990 (2.503 billion) to 2010

83 Around a third of global DALYs attributable to mental, neurological, and substanc

84 5 years of age) declining from 41% of global DALYs in 1990 to 25% in 2010.

85 tion accounting for 0.9% (0.4-1.6) of global DALYs in 2010.

86 seases were the 18th leading cause of global DALYs in Global Burden of Disease 2013.

87 6% of total global deaths and 4.2% of global DALYs, 59% of these in east and south Asia.

88 Nine countries had significantly greater DALYs from cutaneous leishmaniasis than the mean: Afghan

89 .3), and east Asia (56.5), with the greatest DALY burdens in children, adolescents, and the elderly.

90 haran Africa, and south Asia had the highest DALYs from cutaneous leishmaniasis.

91 9, Vietnam: $1407) and 'cost-effective' if $/DALY was less than three times per capita GDP.

92 An important shift has occurred in DALY composition with the contribution of deaths and dis

93 infections (top rank in 1990; 44% decline in DALYs), stroke (fifth in 1990; 19% increase), diarrhoeal

94 o fetal losses was included and decreases in DALYs when comprehensive CT prevention measures were con

95 The disease burden was expressed in DALYs, which are the sum of Years Lost due to Disability

96 3.5 billion in 2015, with a 64% increase in DALYs due to oral conditions throughout the world.

97 Most increases in DALYs, especially from non-communicable diseases, were d

98 to the global burden of disease measured in DALYs from 306 diseases and injuries in 2013.

99 5-92.2) of the stroke burden (as measured in DALYs) was attributable to the modifiable risk factors a

100 Substantial reduction in DALYs can be achieved at a relatively modest budget impa

101 n), foodborne trematodosis with 2.02 million DALYs (95% UI 1.65-2.48 million) and foodborne toxoplasm

102 In 2013, an estimated 10.08 million DALYs were attributable to previous exposure to HIV, HBV

103 We estimate that roughly 1 million DALYs were averted across the 22 districts, at a mean in

104 conditions combined accounted for 15 million DALYs globally (1.9% of all YLDs; 0.6% of all DALYs), im

105 00 additional annual deaths and 13.2 million DALYs.

106 inactivity was responsible for 13.4 million DALYs worldwide.

107 all developed countries combined (50 million DALYs).

108 by up to 32,000, and avert up to 2.6 million DALYs at an estimated annual direct medical cost of US$2

109 tiary treatment, which prevented 6.6 million DALYs at an incremental cost-effectiveness ratio of $224

110 rs were found in China and India (66 million DALYs), a number greater than all developed countries co

111 Human cysticercosis with 2.78 million DALYs (95% UI 2.14-3.61 million), foodborne trematodosis

112 DU was estimated to cause 4.0% (2.82 million DALYs, 95% UI 2.4 million to 3.8 million) of DALYs due t

113 ling can also avoid the loss of 0.98 million DALYs, but this option incurs more costs than it saves c

114 g in 25.2 million (95% UI 17.5-37.0 million) DALYs.

115 sing 4.07 million (95% UI 2.49-6.27 million) DALYs.

116 ated 6.64 million (95% UI 5.61-8.41 million) DALYs.

117 in 8.78 million (95% UI 7.62-12.51 million) DALYs.

118 and 78.7 million (95% UI 65.0-97.7 million) DALYs in 2010.

119 of 4.1 million (1.6 million to 6.8 million) DALYs from chronic obstructive pulmonary disease in 2015

120 Mean percent change of DALY rate from 1990 to 2015 was less than 8% in all worl

121 maldehyde accounted for the vast majority of DALY losses caused by IAPs considered in this analysis,

122 tivity analyses to examine the robustness of DALY estimates.

123 r proportion of the disease burden (75.0% of DALYs).

124 e to HIV, 1.1% (216 000, 101 000-338 000) of DALYs due to HBV, and 39.1% (7.05 million, 5.88 million

125 timates suggesting 21.2% of YLDs and 7.1% of DALYs.

126 to 2013 and accounted for more than 3.1% of DALYs.

127 o increased, accounting for more than 10% of DALYs in 2013.

128 Scabies was responsible for 0.21% of DALYs from all conditions studied by GBD 2015 worldwide.

129 in the UK was tobacco (11.8% [10.5-13.3] of DALYs), followed by increased blood pressure (9.0 % [7.5

130 In 1990, 47% of DALYs worldwide were from communicable, maternal, neonat

131 th other developing countries (around 50% of DALYs attributable to non-communicable disease), whereas

132 the poorest countries, compared with 51% of DALYs in high-income countries.

133 k factors accounted for 39.6% (37.7-41.7) of DALYs; leading behavioural risk factors were suboptimal

134 resembled developed countries (around 80% of DALYs attributable to non-communicable disease).

135 s highest in Qatar and accounted for 4.9% of DALYs, followed by 4.8% in the United Arab Emirates, whe

136 actors accounted for 34.5% (32.4 to 36.9) of DALYs; the two leading behavioural risk factors were unh

137 outh Asia (69.41) had the greatest burden of DALYs from scabies.

138 , childhood wasting was the leading cause of DALYs in Afghanistan, Somalia, and Yemen, whereas unsafe

139 cable risk factors were the leading cause of DALYs in high-income and middle-income countries in the

140 aemic heart disease was the leading cause of DALYs in male individuals (6.0%).

141 emic heart disease, and the leading cause of DALYs was low back and neck pain.

142 aemic heart disease was the leading cause of DALYs worldwide in 2010 (up from fourth rank in 1990, in

143 In 2013, the leading five causes of DALYs were diabetes, ischaemic heart disease, chronic ki

144 in Aguascalientes to 14.9% in Chihuahua) of DALYs in Mexico for young people aged 20-24 years.

145 were compared with independent estimates of DALYs lost due to disease.

146 05 million, 5.88 million to 8.15 million) of DALYs due to HCV.

147 DALYs, 95% UI 2.4 million to 3.8 million) of DALYs due to HIV, 1.1% (216 000, 101 000-338 000) of DAL

148 prioritized children] reduces the number of DALYs by 9% (for the same budget) or alternatively incur

149 The number of DALYs due to listeriosis was lower than those due to con

150 ) or alternatively incurs the same number of DALYs with a 61% reduction in cost.

151 The proportion of DALYs attributed to high body-mass index increased from

152 ons contributed to the highest proportion of DALYs overall (6.0%), and in female indivduals (6.1%), b

153 -adjusted life-years (DALYs) by quintiles of DALYs annual increase from 1990 to 2013 to show rates of

154 increase from 1990 to 2013 to show rates of DALYs increase by burden.

155 aged, YLDs have comprised a larger share of DALYs than have YLLs.

156 resulted in the highest burdens in terms of DALYs, mainly due to years lived with disability.

157 ascular and circulatory diseases in terms of DALYs.

158 e population attributable fractions based on DALYs for specific risk factors.

159 per DALY averted for low risk, and $4.0 per DALY averted for high risk.

160 nets for malaria prevention ($6.48-22.04 per DALY).

161 dian CERs of caesarean sections ($315.12 per DALY) and orthopaedic surgery ($381.15 per DALY) are mor

162 Y averted) and WHO guidelines (ICER $127 per DALY averted), and remained highly cost effective even i

163 mental cost-effectiveness ratio of $1331 per DALY averted.

164 per DALY), and ophthalmic surgery ($136 per DALY) were similar to that of the BCG vaccine ($51.86-22

165 r DALY) and orthopaedic surgery ($381.15 per DALY) are more favourable than those of medical treatmen

166 of only school-aged children (ICER $167 per DALY averted) and WHO guidelines (ICER $127 per DALY ave

167 ess ratio (ICER) of Xpert scale-up ($169 per DALY averted, 95% credible interval [CrI] 104-265) is be

168 er muL or less ranged from $237 to $1691 per DALY averted compared with 2010 guidelines.

169 accompanying improvements to care ($1760 per DALY averted).

170 The ICER for HIV-negative women was $6.2 per DALY averted.

171 g antiretroviral therapy ($453.74-648.20 per DALY).

172 mental cost-effectiveness ratio of $2241 per DALY averted, when compared with that of primary prevent

173 positive adults ranged from $131 to $241 per DALY averted, and in Vietnam extending eligibility to pa

174 r clinical case averted and $80 (44-279) per DALY averted for the three-dose schedule, and of $25 (16

175 cost-effectiveness ratio (ICER) of $7.28 per DALY averted.

176 s of 500 cells per muL or less cost $290 per DALY averted.

177 47.74 per DALY), general surgery ($82.32 per DALY), hydrocephalus surgery ($108.74 per DALY), and oph

178 -effective at $149 (cost saving to $387) per DALY averted.

179 o that of the BCG vaccine ($51.86-220.39 per DALY).

180 moderate risk of low birthweight, $19.4 per DALY averted for low risk, and $4.0 per DALY averted for

181 ost-effectiveness threshold above $1,400 per DALY, canine interventions are at least 95% likely to be

182 emental cost-effectiveness ratio of $469 per DALY averted when compared with the status quo of no cov

183 gross domestic product per capita ($487) per DALY averted, and remain robust over a wide range of epi

184 a cost effectiveness threshold of US$500 per DALY averted, and discounted DALYs and costs at 3% per y

185 ischaemic heart disease ($500.41-706.54 per DALY) and HIV treatment with multidrug antiretroviral th

186 cost-effectiveness ratio (ICER) of $540 per DALY averted, $645 per life-year saved, and $511 per QAL

187 would probably be cost-effective (US$571 per DALY averted).

188 uld be prevented at $1,692 ($634-$4,603) per DALY averted.

189 sensitivity analyses, the ICER was $7.7 per DALY averted for moderate risk of low birthweight, $19.4

190 er DALY), hydrocephalus surgery ($108.74 per DALY), and ophthalmic surgery ($136 per DALY) were simil

191 Rs of cleft lip or palate repair ($47.74 per DALY), general surgery ($82.32 per DALY), hydrocephalus

192 inating the previous guidelines) to $749 per DALY averted.

193 t of standard vaccinations ($12.96-25.93 per DALY) and bednets for malaria prevention ($6.48-22.04 pe

194 ive, and calculated the incremental cost per DALY averted ($/DALY) to compare competing strategies.

195 22 districts, at a mean incremental cost per DALY averted of $46 (SD 10).

196 e greatest impact at an incremental cost per DALY averted of $5588 when compared with coverage of pri

197 In South Africa, the cost per DALY averted of extending ART eligibility to CD4 </=500

198 In South Africa, the cost per DALY averted of extending eligibility for antiretroviral

199 Societal cost per DALY averted was $10, and the cost per rotavirus case av

200 In the base-case analysis, the net cost per DALY averted was $833 compared to CTX alone.

201 regarded very cost effective if the cost per DALY averted was less than the country's 2012 per-head g

202 m: $1407) and cost effective if the cost per DALY averted was less than three times the per-head GDP.

203 ty and mortality, but incurs a high cost per DALY averted, resulting in lost opportunities to generat

204 outcome measure was the incremental cost per DALY averted.

205 .043 per 1000 to cost 0.5 per capita GDP per DALY.

206 0 in Nigeria, to cost 0.5 per capita GDP per DALY.

207 follow-on test to microscopy, would produce DALY gains at a higher incremental cost and therefore is

208 We projected DALYs from 2013 to 2025 for mental, neurological, and su

209 as a direct result of oral diseases is rare, DALY estimates were based on years lived with disability

210 Regionally, DALYs per 100,000 population were highest in the African

211 8 countries, as measured with stroke-related DALYs in 1990 and 2013.

212 We used data on stroke-related DALYs, risk factors, and PAF from the GBD 2013 Study to

213 in diseases were matched to their respective DALYs from GBD 2010.

214 8 diseases were matched to their respective DALYs from the GBD 2010 project.

215 world regions of east Asia (age-standardised DALYs 136.32), southeast Asia (134.57), Oceania (120.34)

216 bies burden were Indonesia (age-standardised DALYs 153.86), China (138.25), Timor-Leste (136.67), Van

217 gest standard deviations of age-standardised DALYs between the 20 age groups were observed in southea

218 In 2013, the global mean age-standardised DALYs for cutaneous leishmaniasis was 0.58 per 100 000 p

219 me time period, the rate of age-standardised DALYs was reduced overall by 19.8% (17.9 to 22.0).

220 ures with population data, we calculated the DALYs attributable to exposures at each site.

221 ne, resulting in 76% (95% UI 65%-81%) of the DALYs attributable to these diseases.

222 re considered 'very cost-effective' if the $/DALY was less than the country's per capita gross domest

223 derrepresented in the CDSR relative to their DALY.

224 the second and third largest contributors to DALYs.

225 The leading risk factors related to DALYs were dietary risks, tobacco smoking, high body mas

226 ubcutaneous diseases composed 0.12% of total DALYs.

227 ollectively accounted for 99.2% of the total DALYs for the chemicals evaluated.

228 accounted for 14.3% (95% UI 12.8-15.9) of UK DALYs in 2010.

229 f disease due to incident hip fracture using DALYs in prospective cohorts in the CHANCES consortium,

230 d YLLs reduced by 41.1% (38.3-43.6), whereas DALYs were reduced by 23.8% (20.9-27.1), and YLDs by 1.4

231 While DALYs due to severe periodontitis and untreated caries i

232 esentation in CDSR is partly correlated with DALY metrics.

233 For women, DALY rates from breast cancer also increased since 1990,

234 ntal cost per disability adjusted life year (DALY) averted compared against gross national income per

235 , US$166) per Disability Adjusted Life Year (DALY) averted, PMI-funded interventions are highly cost-

236 ncidence, and disability-adjusted life year (DALY) estimates of oral conditions for the period of 199

237 e developed a disability-adjusted life year (DALY)-based estimate of the disease burden attributable

238 (in US$) per disability-adjusted life-year (DALY) averted to compare competing strategies.

239 of Avahan per disability-adjusted life-year (DALY) averted versus a no-Avahan counterfactual scenario

240 S dollars per disability-adjusted life-year (DALY) averted.

241 were cost per disability-adjusted life-year (DALY) averted; cost per life-year saved; and cost per qu

242 Disability-adjusted life-year (DALY) changes between 1990 and 2013 were decomposed to q

243 n ($13.78 per disability-adjusted life year [DALY]) was similar to that of standard vaccinations ($12

244 er capita per disability-adjusted life-year [DALY]).

245 0.025 to 6.6 disability-adjusted life years (DALY) per million dollar of final economic demand.

246 der of 0.2-9 disability-adjusted life years (DALY) per year of operation was estimated for the model

247 3.6 million disability-adjusted life-years (DALY) per annum at an incremental cost-effectiveness rat

248 in terms of disability-adjusted life years (DALYs) and identify data gaps.

249 sessed using disability adjusted life years (DALYs) as the common metric.

250 he number of disability-adjusted life years (DALYs) averted by a hydrocelectomy and identified the co

251 ed impact as disability-adjusted life years (DALYs) averted.

252 yphilis, and disability-adjusted life years (DALYs) averted.

253 patterns on disability-adjusted life years (DALYs) by using individual longitudinal data.

254 eart anomaly disability-adjusted life years (DALYs) in the poorest countries, compared with 51% of DA

255 by computing disability-adjusted life years (DALYs) lost due to exposure to secondhand vapor.

256 an number of disability-adjusted life years (DALYs) per child during 6-60 mo of age [which includes c

257 ome regions, disability-adjusted life years (DALYs) per head are 40% higher in low-income and middle-

258 e changes in Disability Adjusted Life Years (DALYs) resulting from changes in exposure to air polluti

259 udy proposed disability-adjusted life years (DALYs) to measure disease burden.

260 to units of disability-adjusted life years (DALYs) using ReCiPe end point analysis method and quanti

261 ar diseases, disability-adjusted life years (DALYs), and life expectancies.

262 deaths, and Disability Adjusted Life Years (DALYs), by age and region for 2010.

263 es of death, disability-adjusted life years (DALYs), DALY-attributable risk factors, years of life li

264 deaths, and Disability Adjusted Life Years (DALYs), for all diseases with sufficient data to support

265 Disability-adjusted life years (DALYs), years lived with disability, and years of life l

266 in terms of Disability Adjusted Life Years (DALYs).

267 measured by disability-adjusted life years (DALYs).

268 s 33 million Disability Adjusted Life Years (DALYs); children under five years old bore 40% of this b

269 1.10 million disability-adjusted life-years (DALYs) and 25% of expected new infections and would prob

270 We used disability-adjusted life-years (DALYs) and years lived with disability (YLDs) metrics to

271 Disability-adjusted life-years (DALYs) are a sum of the years lived with disability and

272 roke-related disability-adjusted life-years (DALYs) associated with potentially modifiable environmen

273 losses, and disability-adjusted life-years (DALYs) attributable to physical inactivity were estimate

274 deaths, and disability-adjusted life-years (DALYs) averted were calculated over a 15 year time horiz

275 ost: 346 000 disability-adjusted life-years (DALYs) averted with an additional cost of US$36.9 millio

276 38-1.48) and disability-adjusted life-years (DALYs) by 27.0 million (25.8-29.1), an increase of 2.7%

277 quantiles of disability-adjusted life-years (DALYs) by quintiles of DALYs annual increase from 1990 t

278 deaths, and disability-adjusted life-years (DALYs) due to listeriosis, by synthesising information a

279 re costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions.

280 e calculated disability-adjusted life-years (DALYs) for low birthweight, severe to moderate anaemia,

281 d $4,746 per disability-adjusted life-years (DALYs) for very cost-effective and cost-effective strate

282 5.1 million) disability-adjusted life-years (DALYs) in 2015, representing 7.6% of total global deaths

283 (YLDs), and disability-adjusted life-years (DALYs) in England, the UK, and 18 other countries (the f

284 ve estimated disability-adjusted life-years (DALYs) lost due to hip fractures using real-life follow-

285 e ratio, and disability-adjusted life-years (DALYs) lost, by age group (aged <75 years, >/= 75 years,

286 h impact, in disability-adjusted life-years (DALYs) lost, due to inhalation of a subset of IAPs in U.

287 s of 420-826 disability-adjusted life-years (DALYs) per 100 000 population.

288 ths or 244.5 disability adjusted life-years (DALYs) per 100 person-years of ART.

289 ing cause of disability-adjusted life-years (DALYs) was ischaemic heart disease for males and lower r

290 Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost

291 Disability-adjusted life-years (DALYs) were estimated as the sum of YLDs and YLLs.

292 and 3.8% of disability-adjusted life-years (DALYs) worldwide.

293 lity (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) in Mexico and

294 lity (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE).

295 and 13.0% of disability-adjusted life-years (DALYs), instead of the earlier estimates suggesting 21.2

296 lity (YLDs), disability-adjusted life-years (DALYs), life expectancy, and healthy life expectancy (HA

297 2.19 million disability-adjusted life-years (DALYs), respectively, and save >51 and 23 billion euros

298 deaths, and disability-adjusted life-years (DALYs), with 95% uncertainty intervals (UIs) calculated

299 and 136 000 disability-adjusted-life-years (DALYs).

300 quivalent to disability-adjusted life-years (DALYs).